Troponin measurements, myocardial infarction diagnoses and outcomes. An analysis of linked data from New South Wales, Australia.
Cardiac troponin assays are a very widely requested test, particularly in emergency departments. Thus, many seriously ill patients who may not have heart disease as their primary discharge diagnosis have undergone troponin testing during hospitalisation. Over a 2-year period (2006-2008) 172,753 hospitalised patients had a quantatitive or qualitative troponin assay performed in New South Wales (Australia). The associations were examined, using data linked to late outcomes, between elevations in levels of troponins T or I and 1-year mortality. Mortality was determined for International Statistical Classification of Diseases 10th Revision (ICD-10-AM) diagnostic groups. Of 172,753 patients undergoing troponin testing 44,357 (25%) had a cardiovascular diagnosis of whom (7% had myocardial infarction) 47,827 (28%) had a probable ischaemic heart disease (IHD) diagnosis if the 23,873 (14%) of patients coded with 'chest pain' were included. In patients with a cardiovascular diagnosis and elevated troponin 3,060 (1.8%) died in 12 months in comparison to 6,262 (3.6%) in those with a non-cardiovascular disease diagnoses and elevated troponin. The 1-year mortality hazard with respect to a troponin elevation was 2.5 (95% Conficence Interval (CI) 2.3-2.7) and 2.0 [95% CIs 1.99-2.01] for those with a cardiovascular and non-cardiovascular diagnosis, respectively. In a very large state-wide hospitalised patient cohort, among patients with elevated troponin levels and non-cardiac diagnoses, mortality was higher than in those with cardiovascular diagnoses, including MI. This article is protected by copyright. All rights reserved.